The Institute for Clinical and Economic Review (ICER) recently assessed two treatments for spinal muscular atrophy (SMA), a rare and deadly genetic condition impacting 1 in 11,000 newborns each year.[1] In the absence of therapy intervention, death or the need for constant ventilation to breathe before the age of two years is the outcome for more than 90% of individuals diagnosed with SMA Type 1. SMA is the number one genetic cause of death for infants.
